International guidelines allow for use of a short-term cancer bioassay (twenty-six weeks) in transgenic mice as a substitute for one of the two required long-term rodent bioassays in the preclinical safety evaluation of pharmaceuticals. The two models that have gained the widest acceptance by sponsors and regulatory authorities are the CB6F1-RasH2 mouse hemizygous for a human H-ras transgene and the B6.129N5-Trp53 mouse heterozygous for a p53 null allele. The p53+/- model is of particular value for compounds with residual concern that genotoxic activity may contribute to tumorigenesis. The rasH2 model is an appropriate alternative without regard to evidence of genotoxic potential. Since results from a short-term bioassay can be obtained relatively early in drug development, there is the potential for more timely assessment of cancer risk for individuals in long-term clinical trials. Use of these models in preclinical safety evaluation also significantly reduces animal use, time, and manpower. Preliminary findings indicate that prediction of two-year rat bioassay outcomes based on data from chronic rat toxicity studies, together with early assessment of carcinogenic potential in short-term transgenic models, may have the potential to increase the timeliness and efficiency of strategies for the identification of human carcinogenic hazards.
Adams, J.M., Harris, A.W., Pinkert, C.A., Corcoran, L.M., Alexander, W.S., Cory, S., Palmiter, R.D., and Brinster, R.L. ( 1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature ( London) 318, 533-38.
2.
Ando, K., Saitoh, A., Hino, O., Takahashi, R., Kimura, M., and Katsuki, M. ( 1992). Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res52, 978-82.
3.
Anisimov, V.N., Ukraintseva, S.V., and Yashin, A.I. ( 2005). Cancer in rodents: Does it tell us about cancer in humans ? Nat Rev Cancer5, 807-19.
4.
Ashby J. ( 2001). Expectations for transgenic rodent cancer bioassay models . Toxicol Pathol29, 177-82.
5.
Berg R.J., de Vries, A., van Steeg, H., and de Gruijl, F.R. ( 1997). Relative susceptibilities of XPA knockout mice and their heterozygous and wild-type littermates to UVB-induced skin cancer . Cancer Res57, 581-84.
6.
Boley, S.E., Anderson, E.E., French, J.E., Donehower, L.A., Walker, D.B. and Recio, L. ( 2000). Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: Evidence of chromosomal recombination. Cancer Res60, 2831-35.
7.
Breuer, M., Slebos, R., Verbeek, S.van Lohuizen, M., Wientjens, E., and Berns, A. ( 1989). Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature ( London) 340, 61-63.
8.
Carmichael, N.G., Debruyne, E.L., and Bigot-Lasserre, D. (2000). The p53 heterozygous knockout mouse as a model for chemical carcinogenesis in vascular tissue. Environ Health Perspect108, 61-65.
9.
Cohen, S.M. ( 2001). Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. Toxicol Pathol29, 183-90.
10.
Cohen, S.M., Storer, R.D., Criswell, K.A., Doerrer, N.G., Dellarco, V.L., Pegg, D.G., Wojcinski, Z.W., Malarkey, D.E., Jacobs, A.C., Klaunig, J.E., Swenberg, J.A., and Cook, J.C. ( 2009). Hemangiosarcoma in rodents: Mode-of-action evaluation and human relevance. Toxicol Sci111, 4-18.
11.
Contrera J.F., and DeGeorge, J.J. ( 1998). In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ Health Perspect106 (Suppl 1), 71-80.
12.
Cui, Q., Ma, Y., Jaramillo, M., Bari, H., Awan, A., Yang, S., Zhang, S., Liu, L., Lu, M., O’Connor-McCourt, M., Purisima, E.O., and Wang, E. ( 2007). A map of human cancer signaling. Mol Syst Biol3, 1-13.
13.
Dennis, C. ( 2006) Cancer: Off by a whisker. Nature442, 739-41.
14.
de Vries, A., van Oostrom C.T., Hofhuis, F.M., Dortant, P.M., Berg, R.J., de Gruijl, F.R., Wester, P.W., van Kreijl, C.F., Capel, P.J., and van Steeg, H. ( 1995). Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature377, 169-73.
15.
de Vries, A., and van Steeg, H. ( 1996). Xpa knockout mice. Semin Cancer Biol7, 229-40.
16.
de Vries, A., van Oostrom, C.T., Dortant, P.M., Beems, R.B., van Kreijl, C.F., Capel, P.J., and van Steeg, H. ( 1997) Spontaneous liver tumors and benzo[a]pyrene-induced lymphomas in XPA-deficient mice. Mol Carcinog19, 46-53.
17.
de Vries, A., Dollé, M.E., Broekhof, J.L., Muller, J.J., Kroese, E.D., van Kreijl, C.F., Capel, P.J., Vijg, J., and van Steeg, H. ( 1997). Induction of DNA adducts and mutations in spleen, liver and lung of XPAdeficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: Correlation with tumour development. Carcinogenesis18, 2327-32.
18.
de Vries, A., van Steeg, H., and Opperhuizen, A. ( 2004). Transgenic mice as alternatives in carcinogenicity testing: Current status. RIVM report 340700001. Available at http://rivm.openrepository.com/rivm/bitstream/10029/8911/1/340700001.pdf . Accesse 14 October 2009.
19.
Dolinoy, D.C., Huang, D., and Jirtle, R.L. ( 2007). Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci U S A104, 13056-61.
20.
Donehower, L.A. ( 1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol7, 269-78.
21.
Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A. Jr , Butel, J.S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumoursNature356, 215-21.
22.
Dunnick, J.K., Hardisty, J.F., Herbert, R.A., Seely, J.C., Furedi-Machacek, E.M., Foley, J.F., Lacks, G.D., Stasiewicz, S., and French, J.E. ( 1997). Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice . Toxicol Pathol25, 533-40.
23.
Eastin, W.C., Haseman, J.K., Mahler, J.F., and Bucher, J.R. ( 1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens . Toxicol Pathol26, 461-73.
24.
Eastin, W.C., Mennear, J.H., Tennant, R.W., Stoll, R.E., Branstetter, D.G., Bucher, J.R., McCullough, B., Binder, R.L., Spalding, J.W., and Mahler, J.F. ( 2001). Tg.AC genetically altered mouse: Assay working group overview of available data. Toxicol Pathol29 (Suppl), 60-80.
25.
French, J.E., Lacks, G.D., Trempus, C., Dunnick, J.K., Foley, J., Mahler, J., Tice, R.R. and Tennant, R.W. ( 2001b). Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent . Carcinogenesis22, 99-10.
26.
French, J., Storer, R.D., and Donehower, L.A. ( 2001a). The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol29 (Suppl), 24-29.
27.
Frese, K.K., and Tuveson, D.A. ( 2007). Maximizing mouse cancer models. Nat Rev Cancer7, 645-58.
28.
Graeber, T.G., and Sawyers, C.L. ( 2005). Cross-species comparisons of cancer signalingNat Genet37, 7-8.
29.
Hahn, W.C., and Weinberg, R.A. ( 2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer2, 331-41.
30.
Harvey, M., McArthur, M.J., Montgomery, C.A. Jr , Butel, J.S., Bradley, A., and Donehower, L.A. (1993a) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet5, 225-29.
31.
Harvey, M., McArthur, M.J., Montgomery, C.A. Jr , Bradley, A., and Donehower, L.A. (1993b). Genetic background alters the spectrum of tumors that develop in p53-deficient mice . FASEB J7, 938-43.
32.
Harvey M., Vogel. H., Morris, D., Bradley, A., Bernstein, A., Donehower, L.A. ( 1995) mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet9, 305-11.
33.
Honchel, R., Rosenzweig, B.A., Thompson, K.L., Blanchard, K.T., Furst, S.M., Stoll, R.E., and Sistare, F.D. ( 2001). Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Mol Carcinog30, 99-110.
34.
International Committee on Harmonization ( 1998). Guidance on testing for carcinogenicity of pharmaceuticals . Fed Reg63, 8983-86.
35.
Jacobs, A. ( 2005) Prediction of 2-year carcinogenicity study results for pharmaceutical products: How are we doing? Toxicol Sci88, 18-23.
36.
Jacobsen-Kram, D. ( 2008) Commentary: Regulatory toxicology and the critical path: Predicting long-term outcomes from short-term studies. Vet Pathol45, 707-9.
37.
Jacobson-Kram, D., Sistare, F.D., and Jacobs, A.C. ( 2004). Use of transgenic mice in carcinogenicity hazard assessment . Toxicol Pathol32 (Suppl 1), 49-52.
38.
Jiang, W., Ananthaswamy, H.N., Muller, H.K., and Kripke, M.L. ( 1999). p53 protects against skin cancer induction by UV-B radiation . Oncogene18, 4247-53.
39.
Jiang, W., Ananthaswamy, H.N., Muller, H.K., Ouhtit, A., Bolshakov, S., Ullrich, S.E., El-Naggar, A.K., and Kripke, M.L. ( 2001). UV irradiation augments lymphoid malignancies in mice with one functional copy of wild-type p53. Proc Natl Acad Sci U S A98, 9790-95.
40.
Jin, M., Takahashi, M., Moto, M., Muguruma, M., Ito, K., Watanabe, K., Kenmochi, Y., Kono, T., Hasumi, K., and Mitsumori, K. ( 2007). Carcinogenic susceptibility of rasH2 mice to troglitazone . Arch Toxicol81, 883-94.
41.
Kemp, C.J., Donehower, L.A., Bradley, A., and Balmain, A. ( 1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell74, 813-22.
42.
Kemp, C.J., Wheldon, T., and Balmain, A. ( 1994). p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet8, 66-69.
43.
Leder, A., Kuo, A., Cardiff, R.D., Sinn, E., and Leder, P. ( 1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci U S A87, 9178-82.
44.
Lee, J.S., Chu, I.S., Mikaelyan, A., Calvisi, D.F., Heo, J., Reddy, J.K., and Thorgeirsson, S.S. (2004). Application of comparative functional genomics to identify best-fit mouse models to study human cancer . Nat Genet36, 1306-11.
45.
MacDonald, J., French, J.E., Gerson, R.J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F.D., Storer, R., and van der Laan, J.W. (2004). The utility of genetically modified mouse assays for identifying human carcinogens:A basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci77, 188-94.
46.
McClain, R.M., Keller, D., Casciano, D., Fu, P., MacDonald, J., Popp, J., Sagartz, J. ( 2001). Neonatal mouse model: Review of methods and results . Toxicol Pathol29 (Suppl), 128-37.
47.
Mitsumori, K., Wakana, S., Yamamoto, S., Kodama, Y., Yasuhara, K., Nomura, T., Hayashi, Y., and Maronpot, R.R. ( 1997). Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors. Mol Carcinog20, 298-307.
48.
Mitsumori, K., Koizumi, H., Nomura, T., and Yamamoto, S. ( 1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol26, 520-31.
49.
Morton, D., Alden, C.L., Roth, A.J., and Usui, T. ( 2002). The Tg rasH2 mouse in cancer hazard identification . Toxicol Pathol30, 139-46.
50.
Ozaki, K., Sukata, T., Yamamoto, S., Uwagawa, S., Seki, T., Kawasaki, H., Yoshitake, A., Wanibuchi, H., Koide, A., Mori, Y., and Fukushima, S. ( 1998). High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele . Cancer Res58, 3806-11.
51.
Ozaki, M., Ozaki, K., Watanabe, T., Uwagawa, S., Okuno, Y., and Shirai, T. ( 2005). Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains. Toxicol Pathol33, 267-71.
52.
Paranjpe, M., Wenk, M., and Smith, G. ( 2008). Transgenic rasH2 mouse: A Model for Dermal Carcinogenesis . Available at http://www.taconic.com/user-assets/Documents/streaming_media/paranjpe_ppt.pdf . Accesse 13 October 2009.
53.
Pritchard, J.B., French, J.E., Davis, B.J., and Haseman, J.K. ( 2003). The role of transgenic mouse models in carcinogen identification . Environ Health Perspect111, 444-54.
54.
Qin, C., Wang, Z., Shang, J., Bekkari, K., Liu, R., Pacchione, S., McNulty, K.A., Ng, A., Barnum, J.E., and Storer, R.D. (forthcoming). Intracisternal A particle genes: Distribution in the mouse genome, acitver subtypes, and potential roles as species-specific mediators of susceptibility to cancer. Mol Carcinog.
55.
Rangarajan, A., and Weinberg, R.A. ( 2003). Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer3, 952-59.
56.
Reddy, V. ( 2007). Evaluation of six- and twelve-month rat toxicity assay as predictors of tumorigenicity. Drug Information Association 43rd Annual Meeting Session 273. Available at http://www.softconference.com/270617. Accesse 13 October 2009.
57.
Robinson, D.E., and MacDonald, J.S. ( 2001). Background and framework for ILSI’s collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol29 (Suppl), 13-19.
58.
Saitoh, A., Kimura, M., Takahashi, R., Yokoyama, M., Nomura, T., Izawa, M., Sekiya, T., Nishimura, S., and Katsuki, M. ( 1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene5, 1195-200.
59.
Schwetz, B., and Gaylor, D. ( 1998). Alternative tests: Carcinogenesis as an example . Environ Health Perspect106 (Suppl 2), 467-71.
60.
Spalding, J.W., Momma, J., Elwell, M.R., and Tennant, R.W. ( 1993). Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. Carcinogenesis14, 1335-41.
61.
Spalding, J.W., French, J.E., Stasiewicz, S., Furedi-Machacek, M., Conner, F., Tice, R.R., and Tennant, R.W. ( 2000). Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci53, 213-23.
62.
Storer, R.D., Cartwright, M.E., Cook, W.O., Soper, K.A., and Nichols, W.W. ( 1995). Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice. Carcinogenesis16, 285-93.
63.
Storer, R.D., French, J.E., Haseman, J., Hajian, G., LeGrand, E.K., Long, G.G., Mixson, L.A., Ochoa, R., Sagartz, J.E., and Soper, K.A. ( 2001). p53+/- hemizygous knockout mouse: Overview of available data. Toxicol Pathol29 (Suppl), 30-50.
64.
Tamaoki, N. ( 2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol29 (Suppl 1), 81-89.
65.
Tennant R.W., Rao, G.N., Russfield, A., Seilkop, S., and Braun, A.G. ( 1993). Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue. Carcinogenesis14, 29-35.
66.
Tennant, R.W., French, J.E., and Spalding, J.W. ( 1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect103, 942-50.
Tennant, R.W., Stasiewicz, S., Eastin, W.C., Mennear, J.H., and Spalding, J.W. ( 2001). The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol Pathol29 (Suppl), 51-59.
69.
Thompson, K.L., Rosenzweig, B.A., and Sistare, F.D. ( 1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol Pathol26, 548-55.
70.
Thompson, K.L., Rosenzweig, B.A., Honchel, R., Cannon, R.E., Blanchard, K.T., Stoll, R.E., and Sistare, F.D. ( 2001). Loss of critical palindromic transgene promoter sequence in chemically induced Tg.AC mouse skin papillomas expressing transgene-derived mRNA. Mol Carcinog32, 176-86.
71.
Torti, V.R., Cobb, A.J., Everitt, J.I., Marshall, M.W., Boorman, G.A., and Butterworth, B.E. (2001). A comparison of toxicity and tumorigenesis in two strains of p53-heterozygous mice: The response to inhaled bromodichloromethane. Toxicol Pathol29 (Suppl), 232-33.
72.
Usui, T., Mutai, M., Hisada, S., Takoaka, M., Soper, K.A., McCullough, B., and Alden, C. ( 2001). CB6F1-rasH2 mouse: Overview of available data . Toxicol Pathol29 (Suppl), 90-108.
73.
van Kriejl, C.F., McAnulty, P.A., Beems, R.B., Vynckier, A., van Steeg, H., Fransson-Steen, R., Alden, C.L., Forster, R., van der Laan, J-W., and Vandenberghe, J. (2001). XPA and XPA/p53+/- knockout mice: Overview of available data. Toxicol Pathol29 (Suppl), 117-27.
74.
van Lohuizen, M., Verbeek, S., Krimpenfort, P., Domen, J., Saris, C., Radaszkiewicz, T., and Berns, A. ( 1989). Predisposition to lymphoma-genesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors . Cell56, 673-82.
75.
van Steeg, H., de Vries, A., van Oostrom, C.T.M., van Benthem, J., Beems, R.B., and van Kriejl, C.F. (2001). DNA repair-deficient XPA and XPA/p53+/- knock-out mice: Nature of the models. Toxicol Pathol29 (Suppl), 109-16.
76.
Waterland, R.A. and Jirtle, R.L. ( 2003) Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol15, 5293-300.
77.
Yamamoto, S., Mitsumori, K., Kodama,Y., Matsunuma, N., Manabe, S., Okamiya, H., Suzuki, H., Fukuda, T., Sakamaki, Y., Sunaga, M., Nomura, G., Hioki, K., Wakana, S., Nomura, T., and Hayashi, Y. ( 1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis17, 2455-61.
78.
Yamamoto, S., Hayashi, Y., Mitsumori, K., and Nomura, T. ( 1997). Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene. Lab Anim Sci47, 121-26.
79.
Yamamoto, S., Urano, K., Koizumi, H., Wakana, S., Hioki, K., Mitsumori, K., Kurokawa, Y., Hayashi, Y., and Nomura, T. ( 1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing . Environ Health Perspect106 (Suppl 1), 57-69.
80.
Yamamoto, S., Urano, K., and Nomura, T. ( 1998). Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing . Toxicol Lett102-103, 473-78.
81.
Yamamoto, M., Tsukamoto, T., Sakai, H., Shirai, N., Ohgaki, H., Furihata, C., Donehower, L.A., Yoshida, K., and Tatematsu, M. ( 2000). p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis21, 1891-97.
82.
Zhang, Y., Maksakova, I.A., Gagnier, L., van de Lagemaat, L.N., and Mager, D.L. ( 2008). Genome-wide assessments reveal extremely high levels of polymorphism of two active families of mouse endogenous retroviral elements . PLoS Genet4 (2), e1000007.
